??????????? ?????????????????????????Duvelisib was the 2nd PI3K inhibitor approved because of the FDA, also based on a period III randomized trial.one hundred thirty The efficacy and basic safety profile from the drug appear equivalent with Individuals of idelalisib, if not marginally advantageous. Pertaining to substitute BTK inhibitors, there are